Shikari® (Q-TRAS) Trastuzumab ELISA
TRA-FD-HH
Enzyme immunoassay for the quantitative determination of Trastuzumab (Herceptin®, Herclon®)in human serum and plasma.
This kit has been especially developed for the quantitative determination of trastuzumab in serum and plasma samples between the Cmin and Cmax range of concentrations.
Trastuzumab Drug Bank Accession Number is DB00072.
Trastuzumab is a monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers. Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2).Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system.
Research Use Only (RUO)
For technical inquiry, IFU and other relevant documents please contact techsupport@matriksbiotek.com
All SHIKARI® ELISA kits are produced under ISO 13485 quality system.
Research Use Only (RUO)
| Required Volume (µl) | 10 |
| Total Time (min) | 70 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 3 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
| # | File | Action |
|---|---|---|
| Safety Data Sheet (SDS) | Download |
Publications with this drug
| # | File | Action |
|---|---|---|
| Mocenigo, Marco, et al. "Rapid, cost-effective peptide/nucleic acid-based platform for therapeutic antibody monitoring in clinical samples." ACS sensors 5.10 (2020): 3109-3115. | Visit Link | |
| Padrón, Ivette Mourani, et al. "Anti-drug antibodies anti-trastuzumab in the treatment of breast cancer." Journal of Oncology Pharmacy Practice 27.6 (2021): 1354-1356. | Visit Link | |
| González García, Jonathan, et al. "Pharmacokinetics of trastuzumab after subcutaneous and intravenous administration in obese patients." Annals of Pharmacotherapy 54.8 (2020): 775-779. | Visit Link | |
| Puente‐Massaguer, Eduard, et al. "A statistical approach to improve compound screening in cell culture media." Engineering in life sciences 19.4 (2019): 315-327. | Visit Link | |
| González-García, Jonathan, et al. "Long-term stability of trastuzumab in plasma and whole blood samples stored under different conditions." Farmacia Hospitalaria 43.2 (2019): 50-52. | Visit Link | |
| González García, Jonathan, et al. "Influence of anthropometric characteristics in patients with Her2-positive breast cancer on initial plasma concentrations of trastuzumab." Annals of Pharmacotherapy 51.11 (2017): 976-980. | Visit Link | |
| Iwamoto, Noriko, Akinobu Hamada, and Takashi Shimada. "Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis." Analytical biochemistry 540 (2018): 30-37. | Visit Link | |
| Chen, Jing, et al. "Tailor-making fluorescent hyaluronic acid microgels via combining microfluidics and photoclick chemistry for sustained and localized delivery of herceptin in tumors." ACS applied materials & interfaces 10.4 (2018): 3929-3937. | Visit Link | |
| Hollevoet, Kevin, et al. "Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies." Oncotarget 9.17 (2018): 13623. | Visit Link | |
| González-García, J., et al. "Plasma levels of trastuzumab in gastric cancer: Case report." Journal of Oncology Pharmacy Practice 23.8 (2017): 635-637. | Visit Link | |
| Genetically modified micro-organ secreting antibody and methods of use Reem MiariNir ShapirInbal ZAFIR-LAVIE | Visit Link | |
| Hollevoet, Kevin, et al. "Bridging the clinical gap for DNA-based antibody therapy through translational studies in sheep." Human Gene Therapy 30.11 (2019): 1431-1443. | Visit Link | |
| Nanoparticle and Macromolecular Transfer across the Human Placental Barrier | Download | |
| Iwamoto, Noriko, and Takashi Shimada. "Method for quantifying monoclonal antibody having antigen or anti-antibody bonded thereto." U.S. Patent No. 11,619,616. 4 Apr. 2023. | Visit Link | |
| Zhou, Xiaofeng, et al. "Novel human single-domain antibodies exert potent anti-tumor activity by targeting EGF-like repeat epitope of EpCAM." Frontiers in Pharmacology 16 (2025): 1530268. | Visit Link |
